Avoid common mistakes on your manuscript.
Authors have submitted a letter to the editor regarding Li L, Zhu X, Chen X, Gao J, Ding C, et al. Advances in targeted therapy for pulmonary arterial hypertension in children. Eur J Pediatr. 2022 Dec 17 [1].
It is a well-written letter and deserves dissemination. We accept the authors’ recommendations on the ambrisentan dosage for treating pulmonary hypertension in children. We hope the letter will be published to provide clinicians with a standardized reference method for using ambrisentan in children with pulmonary hypertension.
Data availability
Not applicable.
References
Li L, Zhu X, Chen X, Gao J, Ding C et al (2022) Advances in targeted therapy for pulmonary arterial hypertension in children. Eur J Pediatr
Funding
This study was supported by the Gansu Provincial Youth Science and Technology Fund (20JR10RA415) and Research Projects of Gansu Provincial Hospital (20GSSY5-2).
Author information
Authors and Affiliations
Contributions
Li Li, Jing Ning and Shixun Ma wrote the main text of the correspondence. All authors reviewed and agreed to the correspondence text.
Corresponding author
Ethics declarations
Ethical approval
Not applicable.
Competing interests
The authors declare no competing interests.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Li, L., Ning, J. & Ma, S. Correspondence, letter to the editor regarding Li L, Zhu X, Chen X, Gao J, Ding C, et al. Advances in targeted therapy for pulmonary arterial hypertension in children. Eur J Pediatr. 2022 Dec 17. Eur J Pediatr 182, 2455 (2023). https://doi.org/10.1007/s00431-023-04896-3
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00431-023-04896-3